









Markets
/
Stocks
/
nasdaq-exas
/

Exact Sciences Corp

EXAS

104.910USD

0.0000.00%

Close 03/26, 16:00（ET）Quotes delayed by 15 min

5.99BMarket Cap

LossP/E TTM



Exact Sciences Corp

104.910

0.0000.00%

Overview Financials Analysis Company

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

Overview

Financials

Analysis

Company

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score of Exact Sciences Corp

Currency: USD Updated: 2026-03-20

Key Insights

Exact Sciences Corp's fundamentals are relatively healthy, with an industry-leading ESG disclosure.and its growth potential is high.Its valuation is considered fairly valued, ranking 50 out of 392 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Hold, with the highest price target at 103.41.In the medium term, the stock price is expected to remain stable.Despite an average stock market performance over the past month, the company shows strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Exact Sciences Corp's Score

Industry at a Glance

Industry Ranking

50 / 392

Overall Ranking

139 / 4546

Industry

Biotechnology & Medical Research

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score

Previous score

Media Coverage

Last 24 hours

Coverage Level

Very Low

Very High

Neutral

Exact Sciences Corp Highlights

StrengthsRisks

Exact Sciences Corporation is a provider of cancer screening and diagnostic tests. The Company provides a portfolio of products for earlier cancer detection and treatment guidance. Its products and services focus on screening and precision oncology tests. It is focusing its research and development efforts on three main areas: Colorectal Cancer Screening Test Development, MCED Test Development and MRD Test Development. Its products and services include Cologuard test, Oncotype DX Breast Recurrence Score Test, Oncotype DX Breast DCIS Score Test, Oncotype DX Colon Recurrence Score Test, OncoExTra Test, and Riskguard Test. Its flagship screening product, the Cologuard test, is a non-invasive, stool-based deoxyribonucleic acid (sDNA) screening test that utilizes a multi-target approach to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. The Oncotype DX Breast Recurrence Score test examines the activity of 21 genes in a patient’s breast tumor tissue.

High Growth

The company's revenue has grown steadily over the past 3 years, averaging 29.89% year-on-year.

Undervalued

The company’s latest PE is -95.19, at a low 3-year percentile range.

Held by CI Select Canadian Equity Fund

Star Investor CI Select Canadian Equity Fund holds 2.35K shares of this stock.

Higher Market Activity

The company has more investor interest, with a 20-day turnover ratio of 0.52.

Analyst Rating

Based on 12 analysts

Hold

Current Rating

105.000

Target Price

+0.09%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Financial Health

Currency: USD Updated: 2026-03-20

The current financial score of Exact Sciences Corp is 7.48, ranking 86 out of 392 in the Biotechnology & Medical Research industry. Its financial status is stable, and its operating efficiency is high. Its latest quarterly revenue reached 878.38M, representing a year-over-year increase of 23.12%, while its net profit experienced a year-over-year increase of 90.06%.

Score

Industry at a Glance

Previous score

7.48

Change



Financials

6.73

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

Relevant data have not been disclosed by the company yet.



Quality of Earnings

5.27

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

Relevant data have not been disclosed by the company yet.



Operational Efficiency

10.00

Key Metrics

Cash flow from operating activities

Income after tax

Relevant data have not been disclosed by the company yet.



Growth Potential

8.05

Key Metrics

Cash flow from operating activities

Total revenue

Relevant data have not been disclosed by the company yet.



Shareholder Returns

7.35

Key Metrics

Free cash flow

Relevant data have not been disclosed by the company yet.

Exact Sciences Corp's Company Valuation

Currency: USD Updated: 2026-03-20

The current valuation score of Exact Sciences Corp is 7.55, ranking 100 out of 392 in the Biotechnology & Medical Research industry. Its current P/E ratio is -95.19, which is -92.33% below the recent high of -7.30 and 0.00% above the recent low of -95.19.

Score

Industry at a Glance

Previous score

7.55

Change

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 50/392

Relevant data have not been disclosed by the company yet.

Earnings Forecast

Currency: USD Updated: 2026-03-20

The current earnings forecast score of Exact Sciences Corp is 6.26, ranking 335 out of 392 in the Biotechnology & Medical Research industry. The average price target is 105.00, with a high of 105.00 and a low of 68.11.

Score

Industry at a Glance

Previous score

6.26

Change

Support & Resistance

Relevant data have not been disclosed by the company yet.

Analyst Rating

Based on 12 analysts

Hold

Current Rating

105.000

Target Price

+0.09%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

548

Total

Median

Average

Company name

Ratings

Analysts

Exact Sciences Corp

EXAS

CRISPR Therapeutics AG

CRSP

IQVIA Holdings Inc

IQV

argenx SE

ARGX

Intellia Therapeutics Inc

NTLA

Beigene Ltd

ONC

...

110

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

Relevant data have not been disclosed by the company yet.

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2026-03-20

The current price momentum score of Exact Sciences Corp is 6.38, ranking 245 out of 392 in the Biotechnology & Medical Research industry. Currently, the stock price is trading between the resistance level at 105.61 and the support level at 103.58, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

5.20

Change

1.18

Support & Resistance

Relevant data have not been disclosed by the company yet.

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(1)

Neutral(0)

Buy(3)

Indicators

Value

Direction

MACD(12,26,9)

0.094

Buy

RSI(14)

76.400

Buy

STOCH(KDJ)(9,3,3)

89.363

Overbought

ATR(14)

0.364

Low Volatility

CCI(14)

295.503

Overbought

Williams %R

3.723

Overbought

TRIX(12,20)

0.034

Sell

StochRSI(14)

100.000

Buy

Moving Average

Sell(0)

Neutral(0)

Buy(6)

Indicators

Value

Direction

MA5

104.074

Buy

MA10

103.769

Buy

MA20

103.574

Buy

MA50

103.023

Buy

MA100

96.139

Buy

MA200

74.294

Buy

Institutional Confidence

Currency: USD Updated: 2026-03-20

The current institutional shareholding score of Exact Sciences Corp is 10.00, ranking 1 out of 392 in the Biotechnology & Medical Research industry. The latest institutional shareholding proportion is 105.49%, representing a quarter-over-quarter decrease of 0.60%. The largest institutional shareholder is The Vanguard, holding a total of 17.37M shares, representing 9.10% of shares outstanding, with 2.27% decrease in holdings.

Score

Industry at a Glance

Previous score

10.00

Change

Institutional Shareholding

Relevant data have not been disclosed by the company yet.

Shareholder Activity

Name

Shares Held

Chg %

The Vanguard Group, Inc.

Star Investors

17.76M

-0.57%

BlackRock Institutional Trust Company, N.A.

7.15M

+1.66%

State Street Investment Management (US)

5.20M

-3.42%

Millennium Management LLC

2.22M

+0.72%

Geode Capital Management, L.L.C.

3.31M

+2.31%

Risk Assessment

Currency: USD Updated: 2026-03-20

The U.S. Dollar Index is currently in a neutral state, which has a neutral effect on the Biotechnology & Medical Research domestic-focused industry. The Dollar Index (DXY) measures the value of the U.S. dollar against a basket of major currencies, including the euro, yen, pound sterling, Canadian dollar, Swedish krona, and Swiss franc. The current risk assessment score of Exact Sciences Corp is 6.44, ranking 26 out of 392 in the Biotechnology & Medical Research industry. The company's beta value is 1.41. This indicates that the stock tends to outperform the index during upward trending markets but experiences larger declines during downward trending markets. with an industry-leading ESG disclosure.